104 related articles for article (PubMed ID: 16250842)
21. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
22. Progress in the discovery of BACE inhibitors.
Thompson LA; Bronson JJ; Zusi FC
Curr Pharm Des; 2005; 11(26):3383-404. PubMed ID: 16250843
[TBL] [Abstract][Full Text] [Related]
23. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease.
Wolfe MS; De Los Angeles J; Miller DD; Xia W; Selkoe DJ
Biochemistry; 1999 Aug; 38(35):11223-30. PubMed ID: 10471271
[TBL] [Abstract][Full Text] [Related]
24. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.
Citron M
Trends Pharmacol Sci; 2004 Feb; 25(2):92-7. PubMed ID: 15102495
[TBL] [Abstract][Full Text] [Related]
25. Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.
Schenk D; Games D; Seubert P
J Mol Neurosci; 2001 Oct; 17(2):259-67. PubMed ID: 11816797
[TBL] [Abstract][Full Text] [Related]
26. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity.
Shearman MS; Beher D; Clarke EE; Lewis HD; Harrison T; Hunt P; Nadin A; Smith AL; Stevenson G; Castro JL
Biochemistry; 2000 Aug; 39(30):8698-704. PubMed ID: 10913280
[TBL] [Abstract][Full Text] [Related]
27. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors.
Aisen PS
CNS Drugs; 2005; 19(12):989-96. PubMed ID: 16332141
[TBL] [Abstract][Full Text] [Related]
28. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
[TBL] [Abstract][Full Text] [Related]
29. Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design.
Moore CL; Leatherwood DD; Diehl TS; Selkoe DJ; Wolfe MS
J Med Chem; 2000 Sep; 43(18):3434-42. PubMed ID: 10978191
[TBL] [Abstract][Full Text] [Related]
30. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
31. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
32. Gamma-secretase: a catalyst of Alzheimer disease and signal transduction.
Li YM
Mol Interv; 2001 Oct; 1(4):198-207. PubMed ID: 14993342
[TBL] [Abstract][Full Text] [Related]
33. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
[TBL] [Abstract][Full Text] [Related]
34. gamma-Secretase inhibitors as molecular probes of presenilin function.
Wolfe MS
J Mol Neurosci; 2001 Oct; 17(2):199-204. PubMed ID: 11816793
[TBL] [Abstract][Full Text] [Related]
35. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway.
Hook VY; Reisine TD
J Neurosci Res; 2003 Nov; 74(3):393-405. PubMed ID: 14598316
[TBL] [Abstract][Full Text] [Related]
36. Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.
Beher D; Wrigley JD; Owens AP; Shearman MS
J Neurochem; 2002 Aug; 82(3):563-75. PubMed ID: 12153480
[TBL] [Abstract][Full Text] [Related]
37. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
38. Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles.
Hook VY; Toneff T; Aaron W; Yasothornsrikul S; Bundey R; Reisine T
J Neurochem; 2002 Apr; 81(2):237-56. PubMed ID: 12064471
[TBL] [Abstract][Full Text] [Related]
39. Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from gamma-secretase.
Campbell WA; Reed ML; Strahle J; Wolfe MS; Xia W
J Neurochem; 2003 Jun; 85(6):1563-74. PubMed ID: 12787075
[TBL] [Abstract][Full Text] [Related]
40. Searching for the most effective screening system to identify cell-active inhibitors of beta-secretase.
Middendorp O; Lüthi U; Hausch F; Barberis A
Biol Chem; 2004 Jun; 385(6):481-5. PubMed ID: 15255179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
